Dr. Albert Bourla, Chairman and Chief Executive Officer of Pfizer Inc., is set to make the most significant changes to the pharmaceutical company’s business model in decades. Having successfully launched and distributed the fastest-growing vaccine in history, Comirnaty, and developed an antiviral therapy, Paxlovid, to combat the SARS-CoV-2 virus, Bourla is shifting the focus of Pfizer’s research and development efforts toward oncology, rare diseases, and commercial products.
The CEO of Pfizer is counting on the company’s commercial success following the tremendous success of its vaccine. The company increased its full-year projections guided by the robust performance of its commercial portfolio, including Eliquis, Vyndaqel, and other innovative treatments such as Padcev, acquired from Seagen, in the field of antibody-drug conjugates. Meanwhile, Bourla has invested pandemic profits in buying life sciences, cutting costs in half, and funding research and development of blockbuster drugs.
Bourla has implemented strategic cost-saving initiatives across multiple areas to drive more than ten billion dollars in savings, which is redirected toward research, development, and commercialization of innovative therapies. He has championed strategic transformations that have positioned the company for future success by focusing on high-impact therapeutic areas such as metabolic diseases, obesity, and novel approaches to treating tumors. As a respected global health expert, Bourla continues to advocate for intellectual property rights, as well as regulatory and policy reforms, to ensure medication accessibility in low-income countries, generate sustainable profits from the sales of innovative specialty therapeutics, and continue funding groundbreaking medical research.
